網膜静脈閉塞症治療の市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、投薬タイプ別、エンドユーザー別、地域別 - 産業予測 2025～2032年

網膜静脈閉塞症治療市場規模は2023年に24億3,000万米ドルと評価され、2024年の25億9,000万米ドルから2032年には42億5,000万米ドルに拡大し、予測期間（2025-2032年）のCAGRは6.4％で成長する見通しです。

網膜静脈閉塞症（RVO）治療市場は、RVOの有病率の上昇と、この疾患に罹患しやすい人口の高齢化に後押しされて、大きな成長を遂げています。網膜血管障害の一つであるRVOは、治療しなければ視力障害につながる可能性があります。同市場では、薬物療法、レーザー療法、手術療法など、主に血液循環の改善と黄斑浮腫の軽減に重点を置いたさまざまな解決策が提供されています。抗VEGF薬は、異常な血管の発達を管理するために特に好まれています。北米や欧州のような地域は先進的なヘルスケアシステムにより市場拡大をリードしているが、アジア太平洋地域はヘルスケア意識の高まりにより急速に台頭してきています。継続的な研究投資、革新的な診断法、個別化された治療アプローチが市場の成長をさらに促進し、患者のケアと治療成績を向上させる。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

網膜静脈閉塞症治療市場規模：疾患タイプ別& CAGR（2025-2032）

• 市場概要
• 網膜中心静脈閉塞症（CRVO）
• 網膜静脈分枝閉塞症（BRVO）

網膜静脈閉塞症治療市場規模：治療タイプ別& CAGR（2025-2032）

• 市場概要
• 抗VEGF
• コルチコステロイド薬
• レーザー治療

網膜静脈閉塞症治療市場規模：投薬タイプ別& CAGR（2025-2032）

• 市場概要
• ブランド
• ジェネリック

網膜静脈閉塞症治療市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 眼科クリニック
• 外来手術センター（ASC）
• 小売薬局

網膜静脈閉塞症治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie Inc.（USA）
• Roche（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Alimera Sciences（USA）
• Aerie Pharmaceuticals, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Taiwan Liposome Company, Ltd.（Taiwan）
• Graybug Vision, Inc.（USA）
• Pfizer Inc.（USA）
• IRIDEX Corporation（USA）
• Lumenis（Israel）
• Nidek Co., Ltd.（Japan）
• Annexin Pharmaceuticals AB（Sweden）
• Outlook Therapeutics, Inc.（USA）
• CalciMedica Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Samsung Bioepis（South Korea）

結論と提言

Retinal Vein Occlusion Treatment Market size was valued at USD 2.43 billion in 2023 and is poised to grow from USD 2.59 billion in 2024 to USD 4.25 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The retinal vein occlusion (RVO) treatment market is experiencing significant growth, fueled by the rising prevalence of RVO and an aging population susceptible to this disorder. RVO, a prevalent retinal vascular issue, can lead to vision impairment if untreated. The market offers a variety of solutions, including medications, laser therapy, and surgical options, primarily focusing on enhancing blood circulation and reducing macular edema. Anti-VEGF medications are particularly favored for managing abnormal blood vessel development. Regions like North America and Europe lead in market expansion due to advanced healthcare systems, while the Asia-Pacific region is rapidly emerging, driven by increased healthcare awareness. Continuous research investment, innovative diagnostics, and personalized treatment approaches are set to further propel market growth, enhancing patient care and outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Vein Occlusion Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Vein Occlusion Treatment Market Segments Analysis

Global Retinal Vein Occlusion Treatment Market is segmented by Disease Type, Treatment Type, Medication Type, End-user and region. Based on Disease Type, the market is segmented into Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). Based on Treatment Type, the market is segmented into Anti-VEGF, Corticosteroid Drugs and Laser Therapy. Based on Medication Type, the market is segmented into Branded and Generics. Based on End-user, the market is segmented into Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers (ASC) and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Vein Occlusion Treatment Market

The market for retinal vein occlusion treatment is propelled by various influential factors, including the increasing prevalence of eye disorders worldwide, a rising elderly demographic, enhanced comprehension of ocular conditions, and the expansion of healthcare infrastructures. Additionally, technological innovations and the development of new therapies significantly boost market growth. The existence of a strong drug pipeline, along with recent drug approvals, plays a vital role in this upward trend. As cases of retinal vein occlusion continue to surge and research on effective treatments intensifies, there is potential for significant market expansion, opening avenues for the adoption of cutting-edge therapeutic solutions for this condition.

Restraints in the Retinal Vein Occlusion Treatment Market

The Retinal Vein Occlusion Treatment market encounters a significant challenge due to a lack of long-term clinical evidence. The effectiveness and safety of various treatment options compared to conventional therapies require more comprehensive evaluation. This uncertainty can hinder the adoption of newer therapies, as both healthcare professionals and patients may be hesitant to embrace treatments that lack robust, long-term studies. Furthermore, the dependence on existing treatments may continue as practitioners seek reassurance about the outcomes of emerging options. Consequently, addressing this restraint is essential for promoting growth and acceptance within the Retinal Vein Occlusion Treatment market.

Market Trends of the Retinal Vein Occlusion Treatment Market

The Retinal Vein Occlusion Treatment market is witnessing significant growth, primarily fueled by the rising prevalence of the condition among the aging population. As more individuals enter older age brackets, the incidence of retinal vein occlusion is expected to increase, necessitating innovative and effective treatment options. This trend is prompting healthcare providers and pharmaceutical companies to develop advanced therapies, including anti-VEGF injections and laser treatments, to cater to the growing patient demographic. As awareness and diagnosis improve, coupled with advancements in treatment modalities, the market is set to expand further, offering lucrative opportunities for stakeholders in the ophthalmology sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Retinal Vein Occlusion Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Global Retinal Vein Occlusion Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Anti-VEGF
• Corticosteroid Drugs
• Laser Therapy

Global Retinal Vein Occlusion Treatment Market Size by Medication Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generics

Global Retinal Vein Occlusion Treatment Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers (ASC)
• Retail Pharmacies

Global Retinal Vein Occlusion Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Treatment Type, Medication Type, End-user)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Medication Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Medication Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Medication Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Medication Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiwan Liposome Company, Ltd. (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IRIDEX Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexin Pharmaceuticals AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations